Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation

    ... H, Müller E, Schwinger W. Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection ... IST. Seven patients (median age at diagnosis, 11 yr) with refractory AAA without a MSD underwent HSCT from matched unrelated (n = 6) ...

    Research Article last updated 07/30/2012 - 2:02pm.

  2. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia ... 2 study involving patients with aplastic anemia that was refractory to immunosuppression to determine whether the oral thrombopoietin ...

    Research Article last updated 07/31/2012 - 2:24pm.

  3. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors

    ... marrow failure syndrome and hypocellular refractory cytopenia of childhood (RCC). Historically, patients ...

    Research Article last updated 03/02/2015 - 12:42pm.

  4. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... in patients 60 years of age or older with relapsed or refractory AML who are ineligible for standard intensive chemotherapy ... In the Selinexor in Older Patient with Relapsed/Refractory AML (SOPRA) study, Karyopharm is evaluating approximately 170 ...

    Clinical Trial last updated 08/26/2016 - 9:21am.

  5. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and ... subjects with high-risk MDS/CMML who have relapsed or are refractory to prior therapy; Cohort 2 will include subjects with AML who have ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  6. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

    ... constitute the "previously treated" and "relapsed/ refractory " MDS populations, and how specifically to define disease ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

    ... Early failure to ESA and a baseline diagnosis of refractory anemia with excess blasts (RAEB)-1 were ...

    Research Article last updated 03/05/2013 - 9:29am.

  8. Promising news for older AML patients

    ... has shown good single-agent activity against relapsed/ refractory AML and, as reported in a phase 1b study at the 2016 annual ...

    Article last updated 07/19/2017 - 11:19am.

  9. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... that can be given to patients with relapsed and/or refractory AML, MDS, or ALL. Status:  ... AML according to WHO classification, with relapsed or refractory disease or newly diagnosed older subjects (greater than or equal ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  10. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... recovery of blood counts (CR/CRi) rate for relapsed and refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... for 12 hours prior to enrollment Relapsed or refractory (resistant) disease, as defined by standard criteria21: ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.